Stephanie Mathews
Registered Nurse · Naples, FLNPI 1255588794
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.9% of the total across 65 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 14.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $764 and has fallen 83.6% since, to $125 in 2024. Among registered nurse clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 65 payments — averaging $20.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sumitomo Pharma America, Inc.$197
- Novo Nordisk$177
- Lilly USA, LLC$129
- Regeneron Healthcare Solutions, Inc.$125
- Jazz Pharmaceuticals Inc.$93
- Boehringer Ingelheim$84
- plus $523 from 12 others
What the payments were for
- Food & beverage$1,30198%
- Education$272%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sumitomo Pharma America, Inc. | 5 | $197 |
| Novo Nordisk | 11 | $177 |
| Lilly USA, LLC | 10 | $129 |
| Regeneron Healthcare Solutions, Inc. | 1 | $125 |
| Jazz Pharmaceuticals Inc. | 5 | $93 |
| Boehringer Ingelheim | 4 | $84 |
| Abbott | 4 | $83 |
| Dexcom, Inc. | 4 | $72 |
| AstraZeneca | 4 | $60 |
| Xeris Pharmaceuticals, Inc. | 3 | $59 |
| Bayer | 3 | $58 |
| Amgen | 3 | $55 |
| IBSA Pharma Inc. | 2 | $34 |
| Tandem Diabetes Care, Inc. | 2 | $32 |
| Amarin Pharma, Inc. | 1 | $23 |
| Merck | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,328 in reported general payments places this provider in the 90th percentile of 185 registered nurse providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 272 | $78,560 |
| TrulicityDulaglutide | 71 | $43,309 |
| XifaxanRifaximin | 35 | $41,448 |
| OzempicSemaglutide | 37 | $37,888 |
| DovatoDolutegravir Sodium/Lamivudine | 13 | $23,372 |
| XareltoRivaroxaban | 84 | $19,737 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 52 | $15,968 |
| LinzessLinaclotide | 26 | $15,142 |
| TradjentaLinagliptin | 43 | $14,949 |
| GemtesaVibegron | 52 | $12,273 |
| Tresiba Flextouch U-100Insulin Degludec | 72 | $10,088 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 44 | $9,805 |
| JardianceEmpagliflozin | 33 | $9,643 |
| JanuviaSitagliptin Phosphate | 32 | $8,781 |
| Atorvastatin Calcium | 492 | $8,719 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Fiasp | $177 | $44,16357 claims |
| Lilly USA, LLCTrulicity | $129 | $43,30971 claims |
| Boehringer IngelheimTradjenta, Jardiance, Jentadueto | $84 | $28,81492 claims |
| MerckJanuvia, Janumet, Belsomra | $19 | $18,17585 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $197 | $12,27352 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 185 registered nurse providers in Florida.
Other registered nurse in Naples
- Carly GeierCape Coral$10K
- Dianne DavidDeland$10K
- Rachel SimsFort Myers$8K
- Shannon BagnellAtlantis$5K
- Marcia JohnsonMiami$4K
- Brigitte MartinezOdessa$3K
- Diana MaciasPort Charlotte$2K
- Alexandria HardyWeston$2K
- Pilar TatumPalm Harbor$2K
- Tran GallagherOrlando$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.